Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
about
Taxanes for adjuvant treatment of early breast cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Systemic treatment strategies for triple-negative breast cancer.Adjuvant treatment for older women with invasive breast cancerAdjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patientsImpact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancerOptimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.Breast cancer (non-metastatic)Presentation and management of docetaxel-related adverse effects in patients with breast cancerOptimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysisThe JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment.Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Senior adult oncology: three cases of advanced cancer in patients of advanced ageChanges in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle.How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.Mammography Screening and Treatment of Breast Cancer in the ElderlyRisk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancerThe German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer.Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.The role of HER-2 in Breast CancerPhase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.Early breast cancer in the older woman.Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in ratsPrevention and Treatment of Bone Metastases in Breast CancerEffectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
P2860
Q24242987-8DC9497D-BD74-440E-B424-35C48FD088D2Q27025860-62D30A0A-B4A6-4D53-96DA-9B301DA5BCFDQ27691414-CDA6D362-2F36-4EAD-AB94-CD8174A6AAAFQ28066744-1EFDA3F4-3CEC-4974-857A-19AF9C219586Q28477739-FC58A5A3-9D37-46A6-B0F5-C4D5667EE6D4Q29994501-D9CD1B59-D1A2-44E1-AE8E-4E85E93E89AFQ30244077-311CD771-0223-4E28-BF63-6164DC075F6CQ30251429-17C23164-A7E5-4593-9BD1-0C1A624F9A90Q33385774-E2561361-48FD-4523-A2BB-69B97F96A99AQ33388534-DC824CCA-3257-4A2A-ABB2-71FE9F6401C9Q33427666-DD1D9C35-C9A0-4F87-BA36-046E2C3235FAQ33446778-ABEFAF7D-18BE-4A42-9EB6-E7BC4D19D445Q33698286-195DFFB1-8FF4-4B10-A321-EEE8B9D69E10Q33698446-E81C0FB2-CBC5-43CA-B8A7-595FBAF566B0Q33785011-5F9E587F-1140-4F7B-A53D-9931FFFC3158Q33789362-F51839C7-F2C3-4AFF-A525-D8180600D0AAQ33826701-0C1E1485-AE96-4A24-9B7D-37F1056BAB21Q33827057-44FA182F-FD20-4567-95C1-04CD67857CC2Q33928825-8F19A9D0-73E0-43A9-BDDA-C32DD9E6C6FAQ33955356-E54A72ED-0499-44D5-81F9-58DB9415F4EBQ33972876-BD737272-52E7-4B9A-AD7F-9FD77204CE57Q34035471-21381B8D-FA9B-42CD-B736-FEFF65291C38Q34096295-46D88905-4952-40B1-A931-B3140EF666D9Q34096336-F2324E90-0434-485E-8371-548CDF0816F1Q34184798-753369A3-7E74-427C-BEF5-94F421A566B0Q34284278-02C3CE5C-212E-43E6-B6D2-9079108D6817Q34293797-457F2A1A-ED40-4204-8D68-1374D50683A3Q34379034-8CDE5210-1DBE-4612-97C0-8EE6C6B5FCF1Q34761601-0F47F471-D14B-4FB1-A65D-D98445943689Q34779671-F8A064D4-90B9-43D8-9BD6-4D0A80E65E6BQ34791139-147E7DA6-044E-4881-9DC3-1107BEC97CADQ35047223-CE008BCC-3E6C-45B0-A502-DF432558B722Q35068343-752BE8A6-AF93-4307-9175-A6738E195DA5Q35237134-002CF44E-D4A9-45FC-9C0B-493DD1988188Q35573019-708BE60E-2BED-44B6-A167-D1FD23E84E82Q35584539-F4732FB5-B98F-4A5E-AB06-B34B761D2C1EQ35688776-AE013D6A-8B9E-446D-8127-B64EBEBA09A3Q35746634-B15037E2-8F79-43AE-9865-13C2FFDBBCCDQ35750652-5E9107D9-385C-4627-B3B7-D19A451C6133Q35786472-D9676937-9C72-4A4A-86A4-42D0427CCE08
P2860
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phase III trial comparing doxo ...... py for operable breast cancer.
@en
Phase III trial comparing doxo ...... py for operable breast cancer.
@nl
type
label
Phase III trial comparing doxo ...... py for operable breast cancer.
@en
Phase III trial comparing doxo ...... py for operable breast cancer.
@nl
prefLabel
Phase III trial comparing doxo ...... py for operable breast cancer.
@en
Phase III trial comparing doxo ...... py for operable breast cancer.
@nl
P2093
P356
P1476
Phase III trial comparing doxo ...... py for operable breast cancer.
@en
P2093
Angel G Negron
Donald A Richards
Frankie Ann Holmes
James H Bordelon
Joanne L Blum
John E Pippen
John Sandbach
Joyce A O'Shaughnessy
Kristi A Boehm
Kristi J McIntyre
P304
P356
10.1200/JCO.2006.06.5391
P407
P577
2006-12-01T00:00:00Z